R01 Application Due Date(s): January 14, 2020, January 14, 2021, and January 14, 2022 by 5:00 PM local time of applicant organization.
R21 Application Due Date(s): January 14, 2020; January 14, 2021, by 5:00 PM local time of applicant organization
This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.